Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Regeneron

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Regeneron's Japan sales performance.

regeneron

Immuno-oncology in 2019: the rapid evolution continues

Immuno-oncology in 2019: the rapid evolution continues

In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and

Sanofi extends growth spurt thanks to Genzyme, Dupixent

Sanofi extends growth spurt thanks to Genzyme, Dupixent CSCC is a rare cancer with no other approved therapies, and that niche positioning helped sales reach $15m in the fourth-quarter, ahead of estimates and booked by Regeneron, Sanofi’s

GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn candidates from Amgen, Regeneron and others.

US, EU regulators back rapid reviews of AZ’s RSV med

US, EU regulators back rapid reviews of AZ’s RSV med Another rival, Regeneron’s antibody suptavumab (REGN2222), was dropped from development in 2017 after a late-stage trial failure.

Havas Lynx Group scoops nine Golds at PM Society Awards

Havas Lynx Group scoops nine Golds at PM Society Awards Meanwhile, Sanofi Genzyme and Regeneron came out on top in the pharma category, collecting five Golds and one Silver. ... Target Award for Secondary Care Advertisement: Cognite for Tillots Pharma. Innovation: Havas Lynx for Sanofi Genzyme and Regeneron.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics